Business Description
GT Biopharma is a San Francisco-based company focused on developing cancer and autoimmune disease treatments. Its work centers on a proprietary technology designed to direct the body's natural killer cells toward diseased cells, with several drug candidates currently moving through early-stage clinical trials targeting blood cancers, solid tumors, and conditions such as lupus. Originally founded in 1965 under the name OXIS International, the company rebranded in 2017 and continues to advance its pipeline toward potential commercialization.
